End-Stage Kidney Disease
Conditions
Interventions
Test Group (Group R):0.33% ropivacaine 30ml [surgical incision lateral transversus abdominis plane (TAP) block 20ml combined with rectus sheath block (RSB) 10ml]
Control group (Group NS):normal saline 30 ml
Sponsors
Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients clinically diagnosed with end-stage kidney disease who are scheduled to undergo kidney transplantation in the near future; 2. aged between 18 and 65 years; 3. with a BMI of 18-30 kg/m²; 4. classified as ASA III to IV; 5. able to communicate effectively and cooperate in completing pain assessment scales and follow-up evaluations; 6. who voluntarily agree to participate and sign an informed consent form after a thorough explanation of the clinical trial content.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously undergone kidney transplantation; 2. those with severe cardiovascular, hepatic, neurological, or pulmonary diseases that prevent them from tolerating general anesthesia; 3. individuals who are allergic to the anesthetic drugs used in the study; 4. patients with psychiatric or neurological disorders that hinder their ability to complete pain assessments and follow-up evaluations; 5. those who have recently used analgesic medications or are undergoing long-term treatment with psychotropic drugs; 6. individuals with alcohol dependence or opioid abuse; 7. patients with contraindications for abdominal wall nerve blocks, such as coagulopathy, infection at the puncture site, or tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| completely painless time after waking up;restlessness score during wakefulness;visual analogue scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| heart rate;mean arterial pressure;15-item quality of recovery scale;Information related to surgery and anesthesia;Postoperative follow-up situation;Adverse reaction monitoring;liver and kidney function; | — |
Countries
China
Contacts
Public ContactChen Qi
Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed